Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37845511

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2023 Nov
First author
Kirkwood JM

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Med. 2024 Feb;30(2):607. doi: 10.1038/s41591-023-02661-5.
    note
    Source null
    related pmid
    37923838
    relationship
    Erratum in
  2. citation
    Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02775-w.
    note
    Source null
    related pmid
    38177857
    relationship
    Erratum in

Authors and identifiers

  1. name
    Kirkwood JM
    type
    Author
  2. name
    Del Vecchio M
    type
    Author
  3. name
    Weber J
    type
    Author
  4. name
    Hoeller C
    type
    Author
  5. name
    Grob JJ
    type
    Author
  6. name
    Mohr P
    type
    Author
  7. name
    Loquai C
    type
    Author
  8. name
    Dutriaux C
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Mackiewicz J
    type
    Author
  11. name
    Rutkowski P
    type
    Author
  12. name
    Arenberger P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kirkwood JM
    type
    Author
  2. name
    Del Vecchio M
    type
    Author
  3. name
    Weber J
    type
    Author
  4. name
    Hoeller C
    type
    Author
  5. name
    Grob JJ
    type
    Author
  6. name
    Mohr P
    type
    Author
  7. name
    Loquai C
    type
    Author
  8. name
    Dutriaux C
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Mackiewicz J
    type
    Author
  11. name
    Rutkowski P
    type
    Author
  12. name
    Arenberger P
    type
    Author
bibliography ids
  1. nci-bib-8d8f2f299937ab0cdc29c7fb
book metadata
content sha256
584c7f6c593d8328a04c14cd192d98504bdf38cf2c732b6e857ace46cc526e55
document type
citation
dois
  1. 10.1038/s41591-023-02583-2
electronic publication date
display
2023 Oct 16
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37845511
immutable id
pubmed:37845511@584c7f6c593d8328a04c14cd192d98504bdf38cf2c732b6e857ace46cc526e55
journal
abbreviation
Nat Med
issn electronic
1546-170X
issn print
1078-8956
issue
11
name
Nature medicine
nlm unique id
9502015
pages
2835-2843
volume
29
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Med. 2024 Feb;30(2):607. doi: 10.1038/s41591-023-02661-5.
    note
    Source null
    related pmid
    37923838
    relationship
    Erratum in
  2. citation
    Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02775-w.
    note
    Source null
    related pmid
    38177857
    relationship
    Erratum in
outcomes validated
false
pmid
37845511
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
d61944a8880e05d1e8cfc9bf96ea239547abe7e23491ca1c472ebc68b89127fd
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2023 Nov
precision
month
year
2023
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37845511/
title
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Preserved source evidence · Not medical advice